Skip to main content

Amantadine News

Adamas Announces FDA Approval for Second Indication for Gocovri as an Adjunctive Treatment to levodopa/carbidopa in Parkinson’s Disease Patients Experiencing OFF Episodes

EMERYVILLE, Calif.--(BUSINESS WIRE)--Feb. 1, 2021-- Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS), a company dedicated to developing and delivering medicines that make a meaningful difference to people...

FDA Approves Osmolex ER (amantadine) for the treatment of Parkinson’s Disease and Drug-Induced Extrapyramidal Reactions

BRIDGEWATER, N.J., Feb. 19, 2018 (GLOBE NEWSWIRE) – Osmotica Pharmaceutical US LLC (“Osmotica” or the “Company”), a privately-held specialty pharmaceutical company developing novel central nervous sy...

FDA Approves Gocovri (amantadine) for the Treatment of Dyskinesia in Parkinson's Disease Patients

EMERYVILLE, Calif., Aug. 24, 2017 (GLOBE NEWSWIRE) – Adamas Pharmaceuticals, Inc. (Nasdaq:ADMS) today announced that the U.S. Food and Drug Administration (FDA) has approved Gocovri (amantadine)...

FDA Medwatch Alert: Cyclobenzaprine HCl and Amantadine HCl by Apace Packaging: Recall - Potential Mislabeling

ISSUE: Apace Packaging LLC is voluntarily recalling one lot of Cyclobenzaprine HCl Tablet, USP 5 mg 50ct Unit Dose, NDC# 50268-190-15, Lot Number 16710 and one lot of Amantadine HCl Capsule, USP 100...

Ask a question

To post your own question to this support group, sign in or create an account.

Further information

Related condition support groups

Chronic Fatigue Syndrome (CFS), Attention-Deficit Hyperactivity Disorder (ADHD), Extrapyramidal Reaction, Fatigue, Head Injury, Influenza, Influenza Prophylaxis, Parkinson's Disease, Sexual Dysfunction, SSRI Induced, Tardive Dyskinesia

Amantadine patient information at Drugs.com